Tipanat 15 — Trifluridine and Tipiracil 15 mg / 6.14 mg

Tipanat 15 is supplied as film-coated tablets for oral administration. Each individual film-coated tablet contains:

• Active Ingredients: Trifluridine — 15 mg; Tipiracil Hydrochloride — 6.14 mg (equivalent to 5 mg of active tipiracil free base).
• Excipient Core: Lactose monohydrate, pregelatinized starch, stearic acid, hypromellose, macrogol 8000, titanium dioxide, and magnesium stearate (blended to maintain strict compound structural stability, uniform gastrointestinal disintegration, and optimal cellular bioavailability).

Pharmacodynamics: Tipanat operates as a systemic antimetabolite combination chemotherapy. Trifluridine acts as a thymidine-based nucleoside analogue; once absorbed into expanding malignant cells, it undergoes intracellular phosphorylation to integrate directly into active DNA strands, triggering structural defects that inhibit further tumor proliferation. Tipiracil functions as a highly potent thymidin phosphorylase (TP) inhibitor. Because raw trifluridine is rapidly degraded via first-pass hepatic metabolism, tipiracil blocks this breakdown pathway, maintaining stable and therapeutic plasma concentrations of trifluridine over extended durations.

Pharmacokinetics: Following oral ingestion, both active components are rapidly processed through the gastrointestinal lining, reaching peak plasma concentration parameters (Cmax) within approximately 2 hours. Trifluridine is primarily cleared via renal filtration routes following metabolic structural conversion. Repeated cyclic dosing schedules show no evidence of dangerous systemic accumulation, provided underlying hepatic and renal clearance pathways are functionally stable.

Tipanat Cream/Tablets 15 mg / 6.14 mg is clinically indicated as monotherapy for adult patients for the treatment of:

• 🔹 Metastatic Colorectal Cancer (mCRC): Treatment of adult patients with metastatic colorectal cancer who have been previously treated with, or are not considered candidates for, available standard therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, anti-VEGF agents, and anti-EGFR agents.
• 🔹 Metastatic Gastric Cancer: Treatment of adult patients with metastatic gastric or gastroesophageal junction adenocarcinoma previously treated with at least two prior systemic chemotherapy regimens for advanced or metastatic disease.

Tipanat 15 administration must be initiated and managed strictly under the supervision of a registered medical oncologist experienced in high-potency antineoplastic therapies:

• Dosing Protocol: The standard initial dose is calculated based on body surface area (BSA), targeting 35 mg/m² orally twice daily. Tablets must be taken within 2 hours after completing morning and evening meals, swallowed whole with a glass of water. Do not crush, split, or chew the tablets.
• Cyclic Schedule: Administered for 5 consecutive days followed by a 2-day rest period during Week 1; repeated for another 5 days of treatment followed by a 2-day rest period during Week 2. This is followed by a mandatory 14-day complete rest period. This cumulative 28-day schedule establishes one complete therapeutic cycle.
• Dose Modifications: Complete blood counts (CBC) must be obtained prior to initiating every individual cycle and on Day 15 of each cycle. Severe hematological suppression (such as absolute neutrophil or platelet drops) or severe gastrointestinal toxicity requires temporary dosing suspensions, treatment delays, or down-graduated dose adjustments until toxicities clear to baseline.

The use of Tipanat 15 tablets is strictly contraindicated or must be heavily restricted under the following clinical profiles:

• ⛔ Hypersensitivity: Documented past history of severe allergic reactions or acute hypersensitivity to trifluridine, tipiracil, or any component of the core excipient structure (including severe lactose intolerance).
• ⛔ Pregnancy and Gestation: Highly embryotoxic and teratogenic. It can cause severe fetal harm when administered to pregnant individuals; hence, use during pregnancy is strictly contraindicated. Breastfeeding must be completely discontinued during active therapy.
• ⛔ Severe Organ Impairment: Contraindicated in patients presenting with end-stage severe renal impairment (CrCl less than 30 mL/min) or severe hepatic impairment (Child-Pugh Class C) due to an absence of clinical safety data.
• ⛔ Pediatric Exclusions: Safety protocols and appropriate usage guidelines have not been established for adolescent or pediatric populations under the age of 18 years.

Co-administration with parallel medical therapies requires precise clinical oversight:

• ⚠️ Thymidine Kinase Substrates: Medications utilizing cell-level thymidine kinase processing path channels (e.g., antiviral agents such as zidovudine, acyclovir, or ganciclovir) may compete directly with trifluridine activation steps, potentially causing decreased clinical efficacy or rising cellular toxicity profiles.
• ⚠️ Fasting Alterations: Taking these tablets on an absolute empty stomach significantly alters the absorption curves of trifluridine, which can elevate gastrointestinal adverse events. Strict post-meal administration protocols must be maintained.

Reproductive guidelines and family planning directives for patients undergoing Tipanat cycles:

• Female Patients: Females of reproductive potential must verify an absolute negative pregnancy status prior to starting treatment and use highly effective contraceptive barriers throughout the treatment course and for at least 6 months following the final tablet intake.
• Male Patients: Due to potential genotoxic structural risks to sperm cells, male patients with female partners of childbearing capacity must use reliable barrier protection (condoms) during the active treatment period and maintain them for at least 3 months following the final dose.

The systemic safety profile of this cytotoxic combination agent involves several anticipated side effects:

• 🔴 Hematological Suppression (Most Common): Severe anemia, neutropenia (diminished white cells increasing systemic vulnerability to infections), thrombocytopenia (low platelets), and leukopenia. Regular blood panel monitoring is mandatory.
• 🟡 Gastrointestinal Distress: Severe diarrhea, bouts of nausea, vomiting, significant loss of appetite (anorexia), localized abdominal pain, and altered taste perceptions (dysgeusia).
• 🟠 Systemic Manifestations: Profound fatigue, generalized weakness (asthenia), unexplained pyrexia (fever), and progressive alopecia (hair thinning or hair loss).

Documented instances of acute clinical overdose with managed oral tablet distribution remain isolated:

• Symptoms: Accidental ingestion of excessive tablet limits triggers a critical escalation of active side effects, leading to severe bone marrow suppression (pancytopenia) alongside acute, severe gastrointestinal sloughing (uncontrolled vomiting and diarrhea).
• Management: There is no specific biochemical antidote. Treatment must be immediately suspended, gastric lavage initiated if caught early, and aggressive supportive care provided to stabilize blood cell counts, restore fluids, and balance electrolyte levels.

Storage parameter control necessary to preserve the chemical potency of the cytotoxic compounds:

• 🌡️ Temperature Controls: Store strictly within the original protective high-density bottle, tightly sealed, in a dry environment sheltered from direct light exposure at temperatures below 30 °C.
• 👶 Safety and Handling: Keep completely out of the sight and reach of children. Given the hazardous cytotoxic nature of the drug, any remaining tablets or discarded container assets must be disposed of according to standard protocols for hazardous medical waste.
• ⏳ Shelf Life: 3 years. Do not ingest any tablets past the definitive expiration date stamped across the box end-flap and bottle body labels.

Genuine Tipanat 15 mg / 6.14 mg manufactured by Natco Pharma Ltd. incorporates layered physical, visual, and digital security measures to verify product authenticity:

• 🛡️ Tamper-Evident Corporate Hologram: A circular or rectangular reflective holographic security seal with micro-engraved NATCO text is affixed directly over the upper opening seam of the cardboard retail box. This seal fractures or leaves a distinct void pattern upon physical removal, indicating a secure chain of first opening.
• 🔗 Interactive Verification QR Code: The exterior cardboard carton features a unique high-resolution security QR code. Scanning this code via a mobile smartphone links the user to Natco Pharma's secure authentication database web portal, providing immediate, verified batch validation details.
• 🔒 Packaging Scheme and Corporate Identity: The clean white front panel of the carton and the matching bottle label feature distinctive fluid, wave-like graphic lines in vibrant red and deep blue colors. The lower section showcases the official dark blue oval NATCO corporate logo underscored by an inner red line. The branding text reads "Tipanat 15" in a bold font, where "Tipanat" is styled in solid blue and "15" stands out in bright red. The trade name is also printed in Hindi characters directly underneath the English name.
• 🔍 Container Architecture and Volumetric Indicators: The text "20 Tablets" is sharply printed in black on both the upper right corner of the carton box and the bottle label, indicating the precise tablet volume. The tablets are housed inside a dense, opaque white medical-grade plastic bottle sealed with a child-resistant safety cap (requires pressing down firmly while twisting counter-clockwise to open). A food-grade silica gel canister is enclosed inside the bottle to absorb internal humidity.
• 🔢 Factory-Stamped Production Metadata: The side panel of the retail box and the white fields of the bottle label feature clear factory-stamped print detailing the Batch Number (Batch No.), Manufacturing Date (Mfg. Date), Expiration Date (Exp. Date), and the Maximum Retail Price (M.R.P.) for the domestic market. All dates, fonts, and numbering characters must perfectly match between the inner bottle label and the exterior retail carton.